-
U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC
- Size:
18 kB
- Last Update:
16.01.2013
-
You can recommend this page to a friend or colleague by completing the form below. The recipient will receive an e-mail with your name, personal message (if desired) and a link to the present webpage.
- Size:
5 kB
- Last Update:
16.01.2013
-
- Size:
30 kB
- Last Update:
15.01.2013
-
Today, Boehringer Ingelheim has more than 44,000 employees at 145 branches worldwide, and with research centres on four continents it can justifiably endorse its claim to be a research-driven company.
- Size:
2 kB
- Last Update:
15.01.2013
-
- Size:
31 kB
- Last Update:
10.01.2013
-
- Size:
1 kB
- Last Update:
10.01.2013
-
- Size:
1 kB
- Last Update:
10.01.2013
-
Boehringer Ingelheim, headquarterd in Germany, is a global business speard around the world, manufacturing and marketing pharmaceuticals, biopharmaceuticals, pharma chemicals and animal health products.
- Size:
3 kB
- Last Update:
7.01.2013
-
- Size:
1 kB
- Last Update:
7.01.2013
-
Lilly and Boehringer Ingelheim formed their diabetes alliance in January 2011, centering on four pipeline compounds representing several of the largest and most promising product classes.
- Size:
12 kB
- Last Update:
7.01.2013